bloodjourГематология и трансфузиологияRussian journal of hematology and transfusiology0234-57302411-3042ООО Издательский дом «Практика»10.35754/0234-5730-2021-66-4-580-592bloodjour-323Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREКлональное кроветворение и его роль в развитии гематологических заболеванийClonal hematopoiesis and its role in the development of hematological diseaseshttps://orcid.org/0000-0001-6591-3183ПетинатиН. А.PetinatiN. A.

Петинати Наталия Арнольдовна, кандидат медицинских наук, старший научный сотрудник лаборатории физиологии кроветворения 

125167, Москва

Natalia A. Petinati, Cand. Sci. (Med.), Senior Researcher, Laboratory of Physiology of Hematopoiesis 

125167, Moscow

loel@mail.ruhttps://orcid.org/0000-0002-7150-0403ДризеН. И.DrizeN. J.

Дризе Нина Иосифовна, доктор биологических наук, профессор, заведующая лабораторией физиологии кроветворения 

125167, Москва

Nina J. Drize, Dr. Sci. (Biol.), Professor, Head of the Laboratory of Physiology of Hematopoiesis 

125167, Moscow

ndrize@yandex.ruФГБУ «Национальный медицинский исследовательский центр гематологии» Министерства здравоохранения Российской ФедерацииРоссияNational Research Center for HematologyRussian Federation202101122021664580592Copyright © Петинати Н.А., Дризе Н.И., 20212021Петинати Н.А., Дризе Н.И.Petinati N.A., Drize N.J.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.htjournal.ru/jour/article/view/323Введение

Введение. Образование клеток крови у  здорового человека обеспечивается поликлональным кроветворением. С  возрастом в  периферической крови обнаруживаются большие клоны, происходящие из  одной клеткипредшественницы, что является проявлением клонального кроветворения. В некоторых случаях у лиц с клональным кроветворением развиваются гематологические заболевания.

Цель обзора — описать и обобщить современные данные о связи клонального кроветворения с гематологическими заболеваниями.

Основные сведения

Основные сведения. Описывается история выявления клонального кроветворения, основные его свойства, наиболее частые мутации в кроветворных клонах, связанные с риском развития миелодиспластического синдрома и острого миелоидного лейкоза. Обсуждается возможный патогенез опухолевой трансформации.

Introduction

Introduction. The formation of blood cells in a healthy individual is ensured by polyclonal hematopoiesis. Recent studies have shown that with age, large clones with a common genetic marker are found in the peripheral blood, i. e. cells originating from a single progenitor cell. This phenomenon is called clonal hematopoiesis. In some cases, people with clonal hematopoiesis develop hematological diseases.

Aim — to describe and summarize current data on the relationship between clonal hematopoiesis and hematological diseases.

Main findings

Main findings. This review describes the history of detection of clonal hematopoiesis, its main properties, the most frequent mutations in hematopoietic clones associated with the risk of transformation into myelodysplastic syndrome, and acute myeloid leukemia. The meaning and possible pathogenesis of tumor transformation are discussed.

клональное кроветворениестволовые кроветворные клеткиострый миелоидный лейкозмиелодиспластический синдроммутацииглубокое секвенированиеclonal hematopoiesishematopoietic stem cellsacute myeloid leukemiamyelodysplastic syndromemutationsnext generation sequencingReferencesDoulatov S., Notta F., Laurenti E., et al. Hematopoiesis: A human perspective. Cell Stem Cell. 2012; 10(2): 120–36. DOI: 10.1016/j.stem.2012.01.006.Doulatov S., Notta F., Laurenti E., et al. Hematopoiesis: A human perspective. Cell Stem Cell. 2012; 10(2): 120–36. DOI: 10.1016/j.stem.2012.01.006.Bonnet D. Biology of human bone marrow stem cells. Clin Exp Med. 2003; 3(3): 140–9. DOI: 10.1007/s10238-003-0017-9.Bonnet D. Biology of human bone marrow stem cells. Clin Exp Med. 2003; 3(3): 140–9. DOI: 10.1007/s10238-003-0017-9.Phillips R.A. Hematopoietic stem cells: Concepts, assays, and controversies. Semin Immunol. 1991; 3(6): 337–47.Phillips R.A. Hematopoietic stem cells: Concepts, assays, and controversies. Semin Immunol. 1991; 3(6): 337–47.Siminovitch L., Mcculloch E.A., Till J.E. The distribution of colony-forming cells among spleen colonies. J Cell Physiol. 1963; 62: 327–36. DOI: 10.1002/jcp.1030620313.Siminovitch L., Mcculloch E.A., Till J.E. The distribution of colony-forming cells among spleen colonies. J Cell Physiol. 1963; 62: 327–36. DOI: 10.1002/jcp.1030620313.Drize N.J., Keller J.R., Chertkov J.L. Local clonal analysis of the hematopoietic system shows that multiple small short-living clones maintain life-long hematopoiesis in reconstituted mice. Blood. 1996; 88(8): 2927–38.Drize N.J., Keller J.R., Chertkov J.L. Local clonal analysis of the hematopoietic system shows that multiple small short-living clones maintain life-long hematopoiesis in reconstituted mice. Blood. 1996; 88(8): 2927–38.Goyal S., Zandstra P.W. Stem cells: Chasing blood. Nature. 2015; 518(7540): 488–90. DOI: 10.1038/nature14203.Goyal S., Zandstra P.W. Stem cells: Chasing blood. Nature. 2015; 518(7540): 488–90. DOI: 10.1038/nature14203.Carrelha J., Meng Y., Kettyle L.M., et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature. 2018; 554(7690): 106–11. DOI: 10.1038/nature25455.Carrelha J., Meng Y., Kettyle L.M., et al. Hierarchically related lineage-restricted fates of multipotent haematopoietic stem cells. Nature. 2018; 554(7690): 106–11. DOI: 10.1038/nature25455.Watson C.J., Papula A.L., Poon G.Y.P., et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020; 367(6485): 1449–54. DOI: 10.1126/science.aay9333.Watson C.J., Papula A.L., Poon G.Y.P., et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science. 2020; 367(6485): 1449–54. DOI: 10.1126/science.aay9333.Jones R.J., Armstrong S.A. Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant. 2008; 14(1 Suppl 1): 12–6. DOI: 10.1016/j.bbmt.2007.10.012.Jones R.J., Armstrong S.A. Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant. 2008; 14(1 Suppl 1): 12–6. DOI: 10.1016/j.bbmt.2007.10.012.Shlush L.I. Age-related clonal hematopoiesis. Blood. 2018; 131(5): 496–504. DOI: 10.1182/blood-2017-07-746453.Shlush L.I. Age-related clonal hematopoiesis. Blood. 2018; 131(5): 496–504. DOI: 10.1182/blood-2017-07-746453.Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26): 2488–98. DOI: 10.1056/NEJMoa1408617.Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26): 2488–98. DOI: 10.1056/NEJMoa1408617.Jaiswal S., Natarajan P., Silver A.J., et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377(2): 111–21. DOI: 10.1056/NEJMoa1701719.Jaiswal S., Natarajan P., Silver A.J., et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017; 377(2): 111–21. DOI: 10.1056/NEJMoa1701719.Genovese G., Kähler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26): 2477–87. DOI: 10.1056/NEJMoa1409405.Genovese G., Kähler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26): 2477–87. DOI: 10.1056/NEJMoa1409405.Desai P., Hassane D., Roboz G.J. Clonal hematopoiesis and risk of acute myeloid leukemia. Best Pract Res Clin Haematol. 2019; 32(2): 177–85. DOI: 10.1016/j.beha.2019.05.007.Desai P., Hassane D., Roboz G.J. Clonal hematopoiesis and risk of acute myeloid leukemia. Best Pract Res Clin Haematol. 2019; 32(2): 177–85. DOI: 10.1016/j.beha.2019.05.007.Adelman E.R., Figueroa M.E. Human hematopoiesis: aging and leukemogenic risk. Curr Opin Hematol. 2021; 28(1): 57–63. DOI: 10.1097/MOH.0000000000000622.Adelman E.R., Figueroa M.E. Human hematopoiesis: aging and leukemogenic risk. Curr Opin Hematol. 2021; 28(1): 57–63. DOI: 10.1097/MOH.0000000000000622.Ayachi S., Buscarlet M., Busque L. 60 years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations. Exp Hematol. 2020; 83: 2–11. DOI: 10.1016/j.exphem.2020.01.008.Ayachi S., Buscarlet M., Busque L. 60 years of clonal hematopoiesis research: From X-chromosome inactivation studies to the identification of driver mutations. Exp Hematol. 2020; 83: 2–11. DOI: 10.1016/j.exphem.2020.01.008.Zink F., Stacey S.N., Norddahl G.L., et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017; 130(6): 742–52. DOI: 10.1182/blood-2017-02-769869.Zink F., Stacey S.N., Norddahl G.L., et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017; 130(6): 742–52. DOI: 10.1182/blood-2017-02-769869.Lyon M.F. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet. 1962; 14(2): 135–48.Lyon M.F. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet. 1962; 14(2): 135–48.Fialkow P.J. The origin and development of human tumors studied with cell markers. N Engl J Med. 1974; 291(1): 26–35. DOI: 10.1056/NEJM197407042910109.Fialkow P.J. The origin and development of human tumors studied with cell markers. N Engl J Med. 1974; 291(1): 26–35. DOI: 10.1056/NEJM197407042910109.Fey M.F., Peter H.J., Hinds H.L., et al. Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe. J Clin Invest. 1992; 89(5): 1438–44. DOI: 10.1172/JCI115733.Fey M.F., Peter H.J., Hinds H.L., et al. Clonal analysis of human tumors with M27 beta, a highly informative polymorphic X chromosomal probe. J Clin Invest. 1992; 89(5): 1438–44. DOI: 10.1172/JCI115733.Abkowitz J.L., Taboada M., Shelton G.H., et al. An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci U S A. 1998; 95(7): 3862–6. DOI: 10.1073/pnas.95.7.3862.Abkowitz J.L., Taboada M., Shelton G.H., et al. An X chromosome gene regulates hematopoietic stem cell kinetics. Proc Natl Acad Sci U S A. 1998; 95(7): 3862–6. DOI: 10.1073/pnas.95.7.3862.Busque L., Patel J.P., Figueroa M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44(11): 1179–81. DOI: 10.1038/ng.2413.Busque L., Patel J.P., Figueroa M.E., et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet. 2012; 44(11): 1179–81. DOI: 10.1038/ng.2413.Laurie C.C., Laurie C.A., Rice K., et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012; 44(6): 642–50. DOI: 10.1038/ng.2271.Laurie C.C., Laurie C.A., Rice K., et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012; 44(6): 642–50. DOI: 10.1038/ng.2271.Xie M., Lu C., Wang J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20(12): 1472–8. DOI: 10.1038/nm.3733.Xie M., Lu C., Wang J., et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014; 20(12): 1472–8. DOI: 10.1038/nm.3733.Steensma D.P., Ebert B.L. Clonal hematopoiesis as a model for premalignant changes during aging. Exp Hematol. 2020; 83: 48–56. DOI: 10.1016/j.exphem.2019.12.001.Steensma D.P., Ebert B.L. Clonal hematopoiesis as a model for premalignant changes during aging. Exp Hematol. 2020; 83: 48–56. DOI: 10.1016/j.exphem.2019.12.001.Luis T.C., Wilkinson A.C., Beerman I., et al. Biological implications of clonal hematopoiesis. Exp Hematol. 2019; 77: 1–5. DOI: 10.1016/j.exphem.2019.08.004.Luis T.C., Wilkinson A.C., Beerman I., et al. Biological implications of clonal hematopoiesis. Exp Hematol. 2019; 77: 1–5. DOI: 10.1016/j.exphem.2019.08.004.Zink F., Stacey S.N., Norddahl G.L., et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017; 130(6): 742–52. DOI: 10.1182/blood-2017-02-769869.Zink F., Stacey S.N., Norddahl G.L., et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood. 2017; 130(6): 742–52. DOI: 10.1182/blood-2017-02-769869.Buscarlet M., Provost S., Zada Y.F., et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018; 132(3): 277–80. DOI: 10.1182/blood-2018-01-829937.Buscarlet M., Provost S., Zada Y.F., et al. Lineage restriction analyses in CHIP indicate myeloid bias for TET2 and multipotent stem cell origin for DNMT3A. Blood. 2018; 132(3): 277–80. DOI: 10.1182/blood-2018-01-829937.de Haan G., Lazare S.S. Aging of hematopoietic stem cells. Blood. 2018; 131(5): 479–87. DOI: 10.1182/blood-2017-06-746412.de Haan G., Lazare S.S. Aging of hematopoietic stem cells. Blood. 2018; 131(5): 479–87. DOI: 10.1182/blood-2017-06-746412.Chambers S.M., Goodell M.A. Hematopoietic stem cell aging: Wrinkles in stem cell potential. Stem Cell Rev. 2007; 3(3): 201–11. DOI: 10.1007/s12015-007-0027-1.Chambers S.M., Goodell M.A. Hematopoietic stem cell aging: Wrinkles in stem cell potential. Stem Cell Rev. 2007; 3(3): 201–11. DOI: 10.1007/s12015-007-0027-1.Snoeck H.-W. Aging of the hematopoietic system. Curr Opin Hematol. 2013; 20(4): 355–61. DOI: 10.1097/MOH.0b013e3283623c77.Snoeck H.-W. Aging of the hematopoietic system. Curr Opin Hematol. 2013; 20(4): 355–61. DOI: 10.1097/MOH.0b013e3283623c77.Beerman I. Accumulation of DNA damage in the aged hematopoietic stem cell compartment. Semin Hematol. 2017; 54(1): 12–8. DOI: 10.1053/j.seminhematol.2016.11.001.Beerman I. Accumulation of DNA damage in the aged hematopoietic stem cell compartment. Semin Hematol. 2017; 54(1): 12–8. DOI: 10.1053/j.seminhematol.2016.11.001.Mollica L., Fleury I., Belisle C., et al. No association between telomere length and blood cell counts in elderly individuals. J Gerontol A Biol Sci Med Sci. 2009; 64(9): 965–7. DOI: 10.1093/gerona/glp065.Mollica L., Fleury I., Belisle C., et al. No association between telomere length and blood cell counts in elderly individuals. J Gerontol A Biol Sci Med Sci. 2009; 64(9): 965–7. DOI: 10.1093/gerona/glp065.Ho T.T., Warr M.R., Adelman E.R., et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature. 2017; 543(7644): 205–10. DOI: 10.1038/nature21388.Ho T.T., Warr M.R., Adelman E.R., et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature. 2017; 543(7644): 205–10. DOI: 10.1038/nature21388.Kramer A., Challen G.A. The epigenetic basis of hematopoietic stem cell aging. Semin Hematol. 2017; 54(1): 19–24. DOI: 10.1053/j.seminhematol.2016.10.006.Kramer A., Challen G.A. The epigenetic basis of hematopoietic stem cell aging. Semin Hematol. 2017; 54(1): 19–24. DOI: 10.1053/j.seminhematol.2016.10.006.Osorio F.G., Rosendahl Huber A., Oka R., et al. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep. 2018; 25(9): 2308–16.e4. DOI: 10.1016/j.celrep.2018.11.014.Osorio F.G., Rosendahl Huber A., Oka R., et al. Somatic mutations reveal lineage relationships and age-related mutagenesis in human hematopoiesis. Cell Rep. 2018; 25(9): 2308–16.e4. DOI: 10.1016/j.celrep.2018.11.014.Tsai F.D., Lindsley R.C. Clonal hematopoiesis in the inherited bone marrow failure syndromes. Blood. 2020; 136(14): 1615–22. DOI: 10.1182/blood.2019000990.Tsai F.D., Lindsley R.C. Clonal hematopoiesis in the inherited bone marrow failure syndromes. Blood. 2020; 136(14): 1615–22. DOI: 10.1182/blood.2019000990.Holstege H., Pfeiffer W., Sie D., et al. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res. 2014; 24(5): 733–42. DOI: 10.1101/gr.162131.113.Holstege H., Pfeiffer W., Sie D., et al. Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis. Genome Res. 2014; 24(5): 733–42. DOI: 10.1101/gr.162131.113.Fabre M.A., McKerrell T., Zwiebel M., et al. Concordance for clonal hematopoiesis is limited in elderly twins. Blood. 2020; 135(4): 269–73. DOI: 10.1182/blood.2019001807.Fabre M.A., McKerrell T., Zwiebel M., et al. Concordance for clonal hematopoiesis is limited in elderly twins. Blood. 2020; 135(4): 269–73. DOI: 10.1182/blood.2019001807.Fabre M.A., Vassiliou G.S. Home and away: Clonal hematopoiesis in sibling transplants. Blood. 2020; 135(18): 1511–2. DOI: 10.1182/blood.2020005717.Fabre M.A., Vassiliou G.S. Home and away: Clonal hematopoiesis in sibling transplants. Blood. 2020; 135(18): 1511–2. DOI: 10.1182/blood.2020005717.Hansen J.W., Pedersen D.A., Larsen L.A., et al. Clonal hematopoiesis in elderly twins: Concordance, discordance, and mortality. Blood. 2020; 135(4): 261–8. DOI: 10.1182/blood.2019001793.Hansen J.W., Pedersen D.A., Larsen L.A., et al. Clonal hematopoiesis in elderly twins: Concordance, discordance, and mortality. Blood. 2020; 135(4): 261–8. DOI: 10.1182/blood.2019001793.Shlush L.I. Clonal hematopoiesis sees Twin Peaks. Blood. 2020; 135(4): 235–6. DOI: 10.1182/blood.2019003869.Shlush L.I. Clonal hematopoiesis sees Twin Peaks. Blood. 2020; 135(4): 235–6. DOI: 10.1182/blood.2019003869.Valent P., Kern W., Hoermann G., et al. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and roads to AML. Int J Mol Sci. 2019; 20(3): 789. DOI: 10.3390/ijms20030789.Valent P., Kern W., Hoermann G., et al. Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and roads to AML. Int J Mol Sci. 2019; 20(3): 789. DOI: 10.3390/ijms20030789.Warren J.T., Link D.C. Clonal hematopoiesis and risk for hematologic malignancy. Blood. 2020; 136(14): 1599–605. DOI: 10.1182/blood.2019000991.Warren J.T., Link D.C. Clonal hematopoiesis and risk for hematologic malignancy. Blood. 2020; 136(14): 1599–605. DOI: 10.1182/blood.2019000991.Loh P.-R., Genovese G., Handsaker R.E., et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018; 559(7714): 350–5. DOI: 10.1038/s41586-018-0321-x.Loh P.-R., Genovese G., Handsaker R.E., et al. Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature. 2018; 559(7714): 350–5. DOI: 10.1038/s41586-018-0321-x.Döhner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N Engl J Med. 2015; 373(12): 1136–52. DOI: 10.1056/NEJMra1406184.Döhner H., Weisdorf D.J., Bloomfield C.D. Acute myeloid leukemia. N Engl J Med. 2015; 373(12): 1136–52. DOI: 10.1056/NEJMra1406184.Desai P., Mencia-Trinchant N., Savenkov O., et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018; 24(7): 1015–23. DOI: 10.1038/s41591-018-0081-z.Desai P., Mencia-Trinchant N., Savenkov O., et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat Med. 2018; 24(7): 1015–23. DOI: 10.1038/s41591-018-0081-z.Abelson S., Collord G., Ng S.W.K., et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018; 559(7714): 400–4. DOI: 10.1038/s41586-018-0317-6.Abelson S., Collord G., Ng S.W.K., et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018; 559(7714): 400–4. DOI: 10.1038/s41586-018-0317-6.Young A.L., Tong R.S., Birmann B.M., et al. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica. 2019; 104(12): 2410–7. DOI: 10.3324/haematol.2018.215269.Young A.L., Tong R.S., Birmann B.M., et al. Clonal hematopoiesis and risk of acute myeloid leukemia. Haematologica. 2019; 104(12): 2410–7. DOI: 10.3324/haematol.2018.215269.Steensma D.P., Bejar R., Jaiswal S., et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1): 9–16. DOI: 10.1182/blood-2015-03-631747Steensma D.P., Bejar R., Jaiswal S., et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1): 9–16. DOI: 10.1182/blood-2015-03-631747Young A.L., Challen G.A., Birmann B.M., et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016; 7: 12484. DOI: 10.1038/ncomms12484.Young A.L., Challen G.A., Birmann B.M., et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016; 7: 12484. DOI: 10.1038/ncomms12484.Higgins A., Shah M.V. Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia. Genes (Basel). 2020; 11(7): 749. DOI: 10.3390/genes11070749.Higgins A., Shah M.V. Genetic and genomic landscape of secondary and therapy-related acute myeloid leukemia. Genes (Basel). 2020; 11(7): 749. DOI: 10.3390/genes11070749.Patel J.P., Gönen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12): 1079–89. DOI: 10.1056/NEJMoa1112304.Patel J.P., Gönen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366(12): 1079–89. DOI: 10.1056/NEJMoa1112304.Buscarlet M., Provost S., Zada Y.F., et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017; 130(6): 753–62. DOI: 10.1182/blood-2017-04-777029.Buscarlet M., Provost S., Zada Y.F., et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017; 130(6): 753–62. DOI: 10.1182/blood-2017-04-777029.Genovese G., Kähler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26): 2477–87. DOI: 10.1056/NEJMoa1409405.Genovese G., Kähler A.K., Handsaker R.E., et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26): 2477–87. DOI: 10.1056/NEJMoa1409405.Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26): 2488–98. DOI: 10.1056/NEJMoa1408617.Jaiswal S., Fontanillas P., Flannick J., et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26): 2488–98. DOI: 10.1056/NEJMoa1408617.Lindsley R.C., Mar B.G., Mazzola E., et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9): 1367–76. DOI: 10.1182/blood-2014-11-610543.Lindsley R.C., Mar B.G., Mazzola E., et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015; 125(9): 1367–76. DOI: 10.1182/blood-2014-11-610543.Heuser M., Thol F., Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016; 113(18): 317–22. DOI: 10.3238/arztebl.2016.0317.Heuser M., Thol F., Ganser A. Clonal hematopoiesis of indeterminate potential. Dtsch Arztebl Int. 2016; 113(18): 317–22. DOI: 10.3238/arztebl.2016.0317.Kadia T.M., Jain P., Ravandi F., et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016; 122(22): 3484–91. DOI: 10.1002/cncr.30203.Kadia T.M., Jain P., Ravandi F., et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016; 122(22): 3484–91. DOI: 10.1002/cncr.30203.Metzeler K.H., Herold T., Rothenberg-Thurley M., et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016; 128(5): 686–98. DOI: 10.1182/blood-2016-01-693879.Metzeler K.H., Herold T., Rothenberg-Thurley M., et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016; 128(5): 686–98. DOI: 10.1182/blood-2016-01-693879.Mason C.C., Khorashad J.S., Tantravahi S.K., et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016; 30(4): 906–13. DOI: 10.1038/leu.2015.337.Mason C.C., Khorashad J.S., Tantravahi S.K., et al. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016; 30(4): 906–13. DOI: 10.1038/leu.2015.337.Sperling A.S., Gibson C.J., Ebert B.L. The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017; 17(1): 5–19. DOI: 10.1038/nrc.2016.112.Sperling A.S., Gibson C.J., Ebert B.L. The genetics of myelodysplastic syndrome: From clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017; 17(1): 5–19. DOI: 10.1038/nrc.2016.112.Takahashi S. Epigenetic aberrations in myeloid malignancies (Review). Int J Mol Med. 2013; 32(3): 532–8. DOI: 10.3892/ijmm.2013.1417.Takahashi S. Epigenetic aberrations in myeloid malignancies (Review). Int J Mol Med. 2013; 32(3): 532–8. DOI: 10.3892/ijmm.2013.1417.Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29(10): 1373–81. DOI: 10.1200/JCO.2010.32.7742.Metzeler K.H., Maharry K., Radmacher M.D., et al. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol. 2011; 29(10): 1373–81. DOI: 10.1200/JCO.2010.32.7742.Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17(1): 13–27. DOI: 10.1016/j.ccr.2009.11.020.Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell. 2010; 17(1): 13–27. DOI: 10.1016/j.ccr.2009.11.020.Cai Z., Kotzin J.J., Ramdas B., et al. Inhibition of infl ammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell. 2018; 23(6): 833–49.e5. DOI: 10.1016/j.stem.2018.10.013.Cai Z., Kotzin J.J., Ramdas B., et al. Inhibition of infl ammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell. 2018; 23(6): 833–49.e5. DOI: 10.1016/j.stem.2018.10.013.Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer. 2013; 109(2): 299–306. DOI: 10.1038/bjc.2013.281.Katoh M. Functional and cancer genomics of ASXL family members. Br J Cancer. 2013; 109(2): 299–306. DOI: 10.1038/bjc.2013.281.Papaemmanuil E., Gerstung M., Malcovati L., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22): 3616–27; quiz 3699. DOI: 10.1182/blood-2013-08-518886.Papaemmanuil E., Gerstung M., Malcovati L., et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22): 3616–27; quiz 3699. DOI: 10.1182/blood-2013-08-518886.Itzykson R., Kosmider O., Renneville A., et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19): 2428–36. DOI: 10.1200/JCO.2012.47.3314.Itzykson R., Kosmider O., Renneville A., et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19): 2428–36. DOI: 10.1200/JCO.2012.47.3314.Papaemmanuil E., Gerstung M., Bullinger L., et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23): 2209–21. DOI: 10.1056/NEJMoa1516192.Papaemmanuil E., Gerstung M., Bullinger L., et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016; 374(23): 2209–21. DOI: 10.1056/NEJMoa1516192.Volkert S., Kohlmann A., Schnittger S., et al. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014; 53(5): 402–10. DOI: 10.1002/gcc.22151.Volkert S., Kohlmann A., Schnittger S., et al. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome. Genes Chromosomes Cancer. 2014; 53(5): 402–10. DOI: 10.1002/gcc.22151.Sebaa A., Ades L., Baran-Marzack F., et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012; 51(12): 1086–92. DOI: 10.1002/gcc.21993.Sebaa A., Ades L., Baran-Marzack F., et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer. 2012; 51(12): 1086–92. DOI: 10.1002/gcc.21993.Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6): 2162–8. DOI: 10.1182/blood-2005-03-1320.Jones A.V., Kreil S., Zoi K., et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005; 106(6): 2162–8. DOI: 10.1182/blood-2005-03-1320.Hartmann L., Metzeler K.H. Clonal hematopoiesis and preleukemia – Genetics, biology, and clinical implications. Genes Chromosomes Cancer. 2019; 58(12): 828–38. DOI: 10.1002/gcc.22756.Hartmann L., Metzeler K.H. Clonal hematopoiesis and preleukemia – Genetics, biology, and clinical implications. Genes Chromosomes Cancer. 2019; 58(12): 828–38. DOI: 10.1002/gcc.22756.Severson E.A., Riedlinger G.M., Connelly C.F., et al. Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood. 2018; 131(22): 2501–5. DOI: 10.1182/blood-2018-03-840629.Severson E.A., Riedlinger G.M., Connelly C.F., et al. Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood. 2018; 131(22): 2501–5. DOI: 10.1182/blood-2018-03-840629.Ptashkin R.N., Mandelker D.L., Coombs C.C., et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018; 4(11): 1589–93. DOI: 10.1001/jamaoncol.2018.2297.Ptashkin R.N., Mandelker D.L., Coombs C.C., et al. Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors. JAMA Oncol. 2018; 4(11): 1589–93. DOI: 10.1001/jamaoncol.2018.2297.Phallen J., Sausen M., Adleff V., et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017; 9(403): eaan2445. DOI: 10.1126/scitranslmed.aan2415.Phallen J., Sausen M., Adleff V., et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017; 9(403): eaan2445. DOI: 10.1126/scitranslmed.aan2415.Gillis N.K., Ball M., Zhang Q., et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: A proof-of-concept, case-control study. Lancet Oncol. 2017; 18(1): 112–21. DOI: 10.1016/S1470-2045(16)30627-1.Gillis N.K., Ball M., Zhang Q., et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: A proof-of-concept, case-control study. Lancet Oncol. 2017; 18(1): 112–21. DOI: 10.1016/S1470-2045(16)30627-1.Gibson C.J., Lindsley R.C., Tchekmedyian V., et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017; 35(14): 1598–605. DOI: 10.1200/JCO.2016.71.6712.Gibson C.J., Lindsley R.C., Tchekmedyian V., et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol. 2017; 35(14): 1598–605. DOI: 10.1200/JCO.2016.71.6712.Mouhieddine T.H., Sperling A.S., Redd R., et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020; 11(1): 2996. DOI: 10.1038/s41467-020-16805-5.Mouhieddine T.H., Sperling A.S., Redd R., et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020; 11(1): 2996. DOI: 10.1038/s41467-020-16805-5.Boettcher S., Wilk C.M., Singer J., et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020; 135(18): 1548–59. DOI: 10.1182/blood.2019003079.Boettcher S., Wilk C.M., Singer J., et al. Clonal hematopoiesis in donors and long-term survivors of related allogeneic hematopoietic stem cell transplantation. Blood. 2020; 135(18): 1548–59. DOI: 10.1182/blood.2019003079.Arends C.M., Weiss M., Christen F., et al. Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Haematologica. 2020; 105(6): e264–7. DOI: 10.3324/haematol.2019.223305.Arends C.M., Weiss M., Christen F., et al. Clonal hematopoiesis in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. Haematologica. 2020; 105(6): e264–7. DOI: 10.3324/haematol.2019.223305.Frick M., Chan W., Arends C.M., et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019; 37(5): 375–85. DOI: 10.1200/JCO.2018.79.2184.Frick M., Chan W., Arends C.M., et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2019; 37(5): 375–85. DOI: 10.1200/JCO.2018.79.2184.Takizawa H., Boettcher S., Manz M.G. Demand-adapted regulation of early hematopoiesis in infection and infl ammation. Blood. 2012; 119(13): 2991–3002. DOI: 10.1182/blood-2011-12-380113.Takizawa H., Boettcher S., Manz M.G. Demand-adapted regulation of early hematopoiesis in infection and infl ammation. Blood. 2012; 119(13): 2991–3002. DOI: 10.1182/blood-2011-12-380113.Chitre S., Stölzel F., Cuthill K., et al. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. Leukemia. 2018; 32(9): 2020–4. DOI: 10.1038/s41375-018-0208-8.Chitre S., Stölzel F., Cuthill K., et al. Clonal hematopoiesis in patients with multiple myeloma undergoing autologous stem cell transplantation. Leukemia. 2018; 32(9): 2020–4. DOI: 10.1038/s41375-018-0208-8.Kato M., Yamashita T., Suzuki R., et al. Donor cell-derived hematological malignancy: A survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia. 2016; 30(8): 1742–5. DOI: 10.1038/leu.2016.23.Kato M., Yamashita T., Suzuki R., et al. Donor cell-derived hematological malignancy: A survey by the Japan Society for Hematopoietic Cell Transplantation. Leukemia. 2016; 30(8): 1742–5. DOI: 10.1038/leu.2016.23.

The authors declare that there are no conflicts of interest present.